Benign Conditions

Benign Prostatic Hyperplasia

Bladder Cancer

Female Urology

Genitourinary Cancers

Genomic Testing

Hormone Therapy

Kidney Cancer

Challenging Anatomy

Innovative Techniques

Laser Lithotripsy

PCNL Tech & Devices

Ureteroscopy Tech & Devices

Kidney Stones

Men's Health

Next-Generation Imaging

Voiding Dysfunction

OAB and Incontinence

Pediatrics

Controveries in Urologic Cancer

Drug Therapy

Prostate Cancer

Sexual Dysfunction

UTUC

Cosmetic Surgery

Urologic Surgery

Business

Practice Management

Malpractice Consult

Health Law & Policy

Media

Case-Based Peer Perspectives

Investigator Perspectives 

Medical World News

Podcasts

Urology Medical Perspectives

UTv Videos

Peer Exchange

Special Report

Virtual Tumor Board

Insights

Medcast

Peers & Perspectives

Conferences

Conference Listing

Conference Previews 

Conference Recaps

Publications

Urology Times Journal

Editorial Advisory Board

Urologists in Cancer Care

Supplements and Featured Publications

Clinical Forums Recaps

CME/CE

Resources

Begin Your Journey: Tackling Burnout

Live Events

Interactive Tools

Job Board

Partners

Treatment Landscape Evolutions

Subscribe

Articles

Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.

The application is seeking an expanded indication of talazoparib plus enzalutamide for mCRPC.  

FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC

The committee voted 4-5 in opposition of a favorable benefit-risk profile.

FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk

Results from the phase 3 AMPLIFY trial are intended to support an application to the FDA for potential approval of 64Cu-SAR-bisPSMA. 

Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer 

The phase 3 study design will now be submitted for final review by the agency. 

Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do not sell my Personnal Information

Urology Times | News & Insights for Urologists & Health Professionals

Facebook

LinkedIn

Spotlight

Peers and Perspectives

Clinical

Case Based Peer Perspectives

Urology Times presents Case-Based Peer Perspectives. In each video, expert physicians provide insight on managing urology-based patient cases that highlight the use of novel agents in clinical practice.

1rem

Navigating Treatment Decisions in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Optimizing Sequential Therapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone-Predominant Disease

Oliver Sartor, MD, discusses how 68galliumPSMA-11 PET-CT imaging is utilized in prostate cancer management, addressing its clinical applications, availability challenges, role in treatment eligibility assessment, unmet needs, and patient case considerations for metastatic castration-resistant prostate cancer (mCRPC).

A 70-Year-Old Man Diagnosed With PSMA-Positive mCRPC

Neal Shore, MD, FACS discusses how a 65-year-old man with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) underwent a treatment journey that included androgen deprivation therapy, docetaxel, cabazitaxel, and enzalutamide before ultimately being evaluated for Lutetium-177 therapy based on PSMA PET imaging and trial data.

Case-Based Peer Perspectives: A 65-Year-Old Man Diagnosed with PSMA-positive mCRPC

Scott T. Tagawa, MD, MS, FACP, FASCO, a medical oncologist specializing in urothelial carcinoma, reviews two patient cases and provides clinical insights on treatment decisions and ongoing research.

A 72-Year-Old Man with Metastatic Urothelial Carcinoma and a 76-Year-Old Man with Locally Advanced, Resectable Urothelial Carcinoma

Paul M. Yonover, MD, FACS, reviews two cases of patients with prostate cancer and provides insights on imaging, biomarker testing, and treatment decision-making.

A 66-Year-Old-Man with Prostate Cancer and a 78-Year-Old Man with Metastatic Prostate Cancer

Stephen J. Freedland, MD, presents the case of a 67-year-old man with metastatic castration-resistant prostate cancer (mCRPC) and discusses the available treatment options and data that influence treatment selection for patients with the disease.

A 67-Year-Old-Man with Metastatic Prostate Cancer

Karim Chamie, MD, presents 2 cases of patients with muscle-invasive bladder cancer (MIBC), reviews the chosen treatment regimens, and details which clinical and non-clinical factors influence treatment recommendations.

A 60-Year-Old Woman With Muscle-Invasive Bladder Cancer and a 77-Year-Old Man With Muscle-Invasive Bladder Cancer

Dr Brian Helfand presents two cases of men with prostate cancer and discusses the role of positron emission tomography (PET)-based imaging in management of patients with the disease.

A 65-Year-Old Man with Prostate Cancer and a 77-Year-Old Man with Prostate Cancer

Neal Shore, MD, FACS, presents the case of a 74-year-old man with metastatic castration-resistant prostate cancer (mCRPC) and discusses the factors that influence treatment selection for patients with the disease.

A 74-Year-Old-Man with Metastatic Prostate Cancer

Jason Hafron, MD, presents the profile of a 66-year-old man with metastatic castration-sensitive prostate cancer, details the available treatment regimens, and discusses clinical trial data on the use of androgen deprivation therapy combined with a treatment-intensifying agent.

A 66-Year-Old-Man with Metastatic Prostate Cancer

Gordon A. Brown, DO, presents the case of a man with prostate cancer, reviews available treatment options, and discusses data on combination androgen deprivation therapy/apalutamide in patients with metastatic castration-sensitive prostate cancer.

A 60-Year-Old Man with Prostate Cancer

Neal Shore, MD, presents the case of a 64-year-old man with metastatic prostate cancer, reviews the potential treatment options, including PARP inhibitors, and highlights the importance of genetic testing when selecting treatment regimens.

A 64-Year-Old-Man with Metastatic Prostate Cancer

Judd W. Moul, MD, FACS, provides insight on screening and diagnosis of prostate cancer, and comments on the use of biomarker tests to aid in risk stratification, management, and treatment.

A 64-Year-Old Man with Elevated PSA Levels

Karim Chamie, MD, reviews a high-risk muscle invasive bladder cancer case and highlights potential treatment options.

A 75-Year-Old Woman with High-Risk Muscle Invasive Bladder Cancer